Insider Selling: SiBone (NASDAQ:SIBN) CEO Sells 5,411 Shares of Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 5,411 shares of SiBone stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $17.70, for a total value of $95,774.70. Following the transaction, the chief executive officer owned 351,319 shares of the company’s stock, valued at $6,218,346.30. This trade represents a 1.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Laura Francis also recently made the following trade(s):

• On Monday, November 17th, Laura Francis sold 11,341 shares of SiBone stock. The shares were sold at an average price of $17.43, for a total value of $197,673.63.
• On Tuesday, November 11th, Laura Francis sold 5,411 shares of SiBone stock. The stock was sold at an average price of $17.06, for a total transaction of $92,311.66.

SiBone Stock Up 1.3%

SIBN stock traded up $0.24 during trading on Wednesday, reaching $18.60. The stock had a trading volume of 472,223 shares, compared to its average volume of 442,797. The company has a quick ratio of 6.62, a current ratio of 7.97 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $807.05 million, a price-to-earnings ratio of -36.47 and a beta of 0.81. SiBone has a one year low of $11.70 and a one year high of $20.05. The company’s 50 day moving average is $15.40 and its two-hundred day moving average is $16.72.

SiBone (NASDAQ:SIBN) last posted its earnings results on Monday, November 10th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. The firm had revenue of $48.66 million for the quarter, compared to analysts’ expectations of $46.67 million. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. SiBone has set its FY 2025 guidance at EPS. Equities research analysts forecast that SiBone will post -0.78 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on SIBN shares. Cantor Fitzgerald set a $25.00 price objective on SiBone and gave the stock an “overweight” rating in a research report on Monday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research note on Wednesday, October 8th. Truist Financial reduced their price target on shares of SiBone from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, October 15th. Finally, Wall Street Zen downgraded shares of SiBone from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, SiBone currently has an average rating of “Moderate Buy” and an average price target of $23.00.

Institutional Trading of SiBone

Several hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in SiBone by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after buying an additional 1,053 shares in the last quarter. Rhumbline Advisers boosted its position in shares of SiBone by 3.6% during the 1st quarter. Rhumbline Advisers now owns 59,721 shares of the company’s stock valued at $838,000 after acquiring an additional 2,100 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of SiBone by 8.3% during the third quarter. Franklin Resources Inc. now owns 29,018 shares of the company’s stock worth $427,000 after purchasing an additional 2,228 shares in the last quarter. ANTIPODES PARTNERS Ltd purchased a new position in shares of SiBone during the first quarter worth about $34,000. Finally, EntryPoint Capital LLC increased its position in shares of SiBone by 21.5% in the first quarter. EntryPoint Capital LLC now owns 14,787 shares of the company’s stock worth $207,000 after purchasing an additional 2,613 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.